CLAIMS

1. Use of a therapeutic agent in the manufacture of a medicament for the treatment of nerve damage in a patient,

the therapeutic agent being a formulation comprising mesenchymal stem cells and/or cells capable of differentiating into mesenchymal stem cells,

wherein the therapeutic agent is to be intravenously administered to the patient; and wherein the therapeutic agent is to be administered to the patient in combination with the stimulation of a nerve of the patient; and

wherein the stimulation of the nerve of the patient is to be applied during a period from before to 6 hours after the administration of the therapeutic agent.

2. Use of a therapeutic agent in the manufacture of a medicament for the treatment of nerve damage in a patient,

the therapeutic agent being a formulation comprising mesenchymal stem cells and/or cells capable of differentiating into mesenchymal stem cells,

wherein the therapeutic agent is to be intravenously administered to the patient; and wherein the therapeutic agent is to be administered to the patient in combination with the stimulation of a nerve of the patient; and

wherein the stimulation of the nerve of the patient is to be applied to at least one area selected from the group consisting of : an area of nerve damage, an area near an area

of nerve damage, and an area capable of compensating for a function of an area of nerve damage.

3. The use according to claim 1 or 2, wherein the stimulation to be applied is at least one selected from the group consisting of : motor stimulation, sensory stimulation, electrical stimulation, magnetic stimulation, language stimulation, and higher brain function stimulation.